Mitsubishi Tanabe Eyes 50% Increase In Arthritis Sales By FY 2017
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharma projects a 50% increase in sales for its two rheumatoid arthritis drugs over the next four years, with an addition of 120 sales people to market them.